Dr. Howard T. Tee, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,998
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME69141
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Martin North Hospital Stuart, FL
- Cleveland Clinic Indian River Hospital Vero Beach, FL
- Orlando Health Sebastian River Hospital Sebastian, FL
Medical groups
- Howard T Tee MD PLLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,998
- Services billed
- 20,311
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 5,256 | 134 |
| Established patient office or other outpatient visit, 30-39 minutes | 4,817 | 1,728 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,245 | 1,006 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 863 | 834 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 630 | 205 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 551 | 179 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 413 | 207 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 383 | 118 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 302 | 48 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 293 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Vero Beach, FL | 1,405 |
| Metoprolol Succinate Other prescribers in Vero Beach, FL | 1,110 |
| Atorvastatin Calcium Other prescribers in Vero Beach, FL | 964 |
| Rosuvastatin Calcium Other prescribers in Vero Beach, FL | 898 |
| Amlodipine Besylate Other prescribers in Vero Beach, FL | 885 |
| Metoprolol Tartrate Other prescribers in Vero Beach, FL | 693 |
| Losartan Potassium Other prescribers in Vero Beach, FL | 560 |
| Sotalol (sotalol hcl) Other prescribers in Vero Beach, FL | 543 |
| Xarelto (rivaroxaban) Other prescribers in Vero Beach, FL | 530 |
| Furosemide Other prescribers in Vero Beach, FL | 515 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 89 payments worth $1,989 in total to this clinician.
| Novo Nordisk Inc | $210 |
|---|---|
| Novartis Pharmaceuticals Corporation | $207 |
| Merck Sharp & Dohme LLC | $202 |
| Pfizer Inc. | $197 |
| Abbott Laboratories | $170 |
| Alnylam Pharmaceuticals Inc. | $105 |
| Bayer HealthCare Pharmaceuticals Inc. | $102 |
| Kestra Medical Technology Services, Inc. | $96.19 |
| Food and Beverage | $1,957 |
|---|---|
| Education | $32.27 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Feb 10, 2025 | Education Ozempic · Diabetes · in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $334 in research payments for these studies, mostly to the institutions running them.
- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
Cvrx, Inc. · Terminated · NCT04502316
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.